Early dissemination rates of Friend murine leukaemia virus variants correlate with late pathogenesis

APMIS

Volumn 110, Issue 12, 2002, Pages 899-912

  Bruland, Torunn ^a   Dai, Hong Yan ^b   Lavik, Liss Anne S ^b   Dalen, Are ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Early virus load; Erythroleukaemia; Friend murine leukaemia virus; Immunosuppression; Long terminal repeat (LTR); Primary infection

Indexed keywords

ADOLESCENT; ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; ERYTHROBLAST; ERYTHROLEUKEMIA; FEMALE; FRIEND LEUKEMIA VIRUS; IMMUNOSUPPRESSIVE TREATMENT; LONG TERMINAL REPEAT; MOUSE; NEWBORN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

3T3 CELLS; AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; B-LYMPHOCYTES; ERYTHROBLASTS; FEMALE; FRIEND MURINE LEUKEMIA VIRUS; HELPER VIRUSES; IMMUNOLOGIC DEFICIENCY SYNDROMES; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MICE; RETROVIRIDAE INFECTIONS; RNA, VIRAL; SPLEEN; T-LYMPHOCYTES; TERMINAL REPEAT SEQUENCES; TUMOR VIRUS INFECTIONS; VIREMIA; VIRULENCE; VIRUS REPLICATION;

EID: 0036982752     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0463.2002.1101209.x     Document Type: Article

References (36)

1. Hasenkrug KJ, Chesebro B. Immunity to retroviral infection: the Friend virus model. Proc Natl Acad Sci USA 1997;94:7811-6.
2. Hasenkrug KJ, Dittmer U. The role of CD4 and CD8 T cells in recovery and protection from retroviral infection: lessons from the Friend virus model. Virology 2000;272:244-9.
3. Troxler DH, Ruscetti SK, Scolnick EM. The molecular biology of Friend virus. Biochim Biophys Acta 1980;605:305-24.
4. Faxvaag A, Dai HY, Aarseth H, Dalen AB. A low oncogenic variant of Friend murine leukemia virus with strong immunosuppressive properties. Arch Virol 1993;131:265-75.
5. Dai HY, Faxvaag A, Troseth GI, Aarseth H, Dalen A. Molecular cloning and characterization of an immunosuppressive and weakly oncogenic variant of Friend murine leukemia virus, FIS-2. J Virol 1994;68:6976-84.
6. Dai HY, Troseth GI, Gunleksrud M, Bruland T, Solberg LA, Aarseth H, et al. Identification of genetic determinants responsible for the rapid immunosuppressive activity and the low leukemogenic potential of a variant of Friend leukemia virus, FIS-2. J Virol 1998;72:1244-51.
7. Fan H. Influences of the long terminal repeats on retrovirus pathogenicity. Seminars in Virology 1990;1:165-74.
8. Athas GB, Starkey CR, Levy LS. Retroviral determinants of leukemogenesis. Crit Rev Oncog 1994;5:169-99.
9. Sourvinos G, Tsatsanis C, Spandidos DA. Mechanisms of retrovirus-induced oncogenesis. Folia Biologica 2000;46:226-32.
10. Bendinelli M, Matteucci D, Friedman H. Retrovirus-induced acquired immunodeficiencies. Adv Cancer Res 1985;45:125-81.
11. Friedman H, Specter S, Bendinelli M. Influence of viruses on cells of the immune response system. Adv Exp Med Biol 1983;162:463-74.
12. Chesebro B, Wehrly K, Cloyd M, Britt W, Portis J, Collins J, et al. Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology 1981;112:131-44.
13. Grist NR, Ross CA, Bell EJ. Neutralization tests. In: Diagnostic Methods in Clinical Virology. Grist NR, Ross CA, Bell EJ. Blackwell Scientific Publications, Oxford, London, Edinburgh, Melbourne, 1990;Chapter 6:66-7.
14. Bruland T, Dai HY, Lavik LAS, Kristiansen LI, Dalen A. Gender-related differences in susceptibility, early virus dissemination and immunosuppression in mice infected with Friend murine leukaemia virus variant FIS-2. J Gen Virol 200l;82:1821-7.
15. Cunningham AJ, Szenberg A. Further improvements in the plaque technique for detecting single antibody-forming cells. Immunology 1968;14:599-601.
16. Evans LH, Morrey JD. Tissue-specific replication of Friend and Moloney murine leukemia viruses in infected mice. J Virol 1987;61:1350-7.
17. Oldstone MB, Aoki T, Dixon FJ. The antibody response of mice to murine leukemia virus in spontaneous infection: absence of classical immunologic tolerance (AKR mice-complement-fixing antibodies-lymphocytic choriomeningitis virus-immunofluorescence-glomerular deposits of antigen-antibody complexes). Proc Natl Acad Sci 1972;69:134-8.
18. Hasenkrug KJ, Brooks DM, Dittmer U. Critical role for CD4+ T cells in controlling retrovirus replication and spread in persistently infected mice. J Virol 1998;72:6559-64.
19. Ho DD. Viral counts count in HIV infection. Science 1996;272:1124-5.
20. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
21. Lifson JD, Nowak MA, Goldstein S, Rossio JL, Kinter A, Vasquez G, Wiltrout TA, Browns C, Schneider D, Wahl L, Lloyd AL, Williams J, Elkins WR, Fauci AS, Hirsch VM. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol 1997;71:9508-14.
22. Haaft PT, Verstrepen B, Überla K, Rosenwirth B, Heeney J. A pathogenic threshold of virus load defined in simian immunodeficiency virus-or simian-human immunodeficiency virus-infected macaques. J Virol 1998;72:10281-5.
23. Staprans SI, Dailey PJ, Rosenthal A, Horton C, Grant RM, Lerche N, Feinberg MA. Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. J Virol 1999;73:4829-39.
24. Watson A, Ranchalis J, Travis B, McLure J, Sutton W, Philip RJ, Hu SH, Haigwood N. Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol 1997;71:284-90.
25. Kina T, Ikuta K, Takayama K, Wada K, Majumdar AS, Wissman IL. The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br J Haematol 2000;109:280-7.
26. Ruscetti SK. Deregulation of erythropoiesis by the Friend spleen focus-forming virus. Int J Biochem Cell Biol 1999;31:1089-109.
27. Sitbon M, Sola B, Evans L, Nishio J, Hayes SF, Nathanson K, et al. Hemolytic anemia and erythroleukemia, two distinct pathogenic effects of Friend MuLV: mapping of the effects to different regions of the viral genome. Cell 1986;47:851-9.
28. Speck NA, Renjifo B, Golemis E, Fredrickson TN, Hartley JW, Hopkins N. Mutation of the core or adjacent LVb elements of the Moloney murine leukemia virus enhancer alters disease specificity. Genes Dev 1990;4:233-42.
29. Golemis E, Li Y, Fredrickson TN, Hartley JW, Hopkins N. Distinct segments within the enhancer region collaborate to specify the type of leukemia induced by nondefective Friend and Moloney viruses. J Virol 1989;63:328-37.
30. Bruland T, Lavik LAS, Dai HY, Dalen A. A glucocorticoid response element (GRE) in the LTR U3 region of the friend murine leukaemia virus variant, FIS-2 enhances virus production in vitro and is a major determinant for sex differences in susceptibility to FIS-2 infection in vivo. J Gen Virol (in press).
31. Jones SM, Moors MA, Ryan Q, Klyczek KK, Blank KJ. Altered macrophage antigen-presenting cell function following Friend leukemia virus infection. Vital Immunol 1992;5:201-11.
32. Mitasov AV, Tsyrlova IG, Kiselev SV, Kozlov VV. Species-nonspecific action of soluble immunosuppressive factor produced by murine immature erythroid cells. Ann NY Acad Sci 1991;628:399-409.
33. Sennikov SV, Eremina LV, Samarin DM, Avdeev IV, Kozlov VA. Cytokine gene expression in erythroid cells. Eur Cytokine Netw 1996;7:771-4.
34. Seledtsov VI, Seledtsova GV, Samarin D, Taraban VY, Sennikov SV, Kozlov VA. Characterization of erythroid cell-derived natural suppressor activity. Immunobiology 1998;198:361-74.
35. Seledtsova GV, Seledtsov VI, Samarin DM, Taraban VIa, Sennikov SV, Kashchenko EA, et al. Role of the transforming growth factor-β in suppression of B-cell blastogenesis mediated by erythroid cells. Biull Eksp Biol Med 1997;124:550-3.
36. Standal T. Unpublished data.